- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522975
Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (BEAT_001)
A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO® With the Standard Treatment EPREX® in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital
-
Bangkok, Thailand, 10700
- Bamrasnaradura Infectious Disease Institute
-
Bangkok, Thailand, 10700
- Bhumibol Adulyadej Hospital
-
Bangkok, Thailand, 10700
- BMA hospital
-
Bangkok, Thailand, 10700
- Chulalongkorn King Memorial hospital
-
Bangkok, Thailand, 10700
- Klongton Hospital
-
Bangkok, Thailand, 10700
- Phramongkutklao Hospital
-
Bangkok, Thailand, 10700
- Rajavithi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects between the age of 18 to 75 years
- Subjects with renal anaemia (haemoglobin 7.5 g/dl to 10 g/dl)
- Subjects who are treatment naïve to epoetin
- Subjects with chronic kidney disease (CKD) stages* 3 and 4 not yet on dialysis (predialysis)
- Subjects willing to provide a written informed consent
Subjects with serum ferritin ≥ 100 μg/L and/or transferrin saturation ≥ 20%
- CKD staging will be based on the five-stage system for classification of CKD based on KDIGO guidelines.
Exclusion Criteria:
- Subjects with anaemia due to other reasons (that is not renal anaemia)
- Subjects on dialysis
- Subjects who have undergone blood transfusion within the last 3 months
- Subjects with major complication such as severe/chronic infections or bleeding, or aluminum toxicity
- Subjects with suspected or known PRCA
- Subjects with a history of aplastic anaemia
- Subjects with uncontrolled diabetes (fasting blood glucose > 240 mg/dl) or uncontrolled hypertension (systolic blood pressure > 180 mm Hg, diastolic blood pressure > 110 mm Hg)
- Subjects with known hypersensitivity to any of the ingredients of the investigational products, the mammalian cell-derived product or human albumin products
- Subjects with history of seizure disorder
- Subjects with hematological disorder (thrombocytopenia, neutropenia, or hemolysis)
- Subjects with hyperparathyroidism (intact parathyroid hormone > 1000 pg/ml)
- Subjects with severe liver dysfunction
- Subjects with congestive heart failure and/or angina (NYHA class III and IV)
- Subjects with myocardial infarction or stroke in the preceding 6 months of screening
- Subjects with active malignancy in the previous 5 years
- Subjects with gastrointestinal bleeding in the past 6 months
- Subjects with immunosuppressive therapy in the previous 3 months
- Subjects with Hepatitis B virus (HbsAg), Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV) and syphilis
- Female subjects who are pregnant, breast-feeding,planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e. bilateral tubal ligation, total hysterectomy or < 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period
- Subjects participating in trials involving erythropoietin in the past 6 months before screening
- Subjects currently participating or participation in an investigational study within 30 days prior screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reference group
Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease. Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight. |
Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease. Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Other Names:
|
Experimental: Experimental group
Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease. Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight. |
Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease. Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean absolute change in haemoglobin(Hb)
Time Frame: 24 weeks
|
Mean absolute change in haemoglobin(Hb) level from baseline to 24 weeks after treatment with EPIAO®/EPREX® in parallel groups (g/dl),respectively."
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean absolute change in weekly epoetin dosage
Time Frame: 24 weeks
|
Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 24 weeks after treatment with EPIAO®/EPREX® in parallel groups (IU/kg/week).
|
24 weeks
|
Frequency of adverse events
Time Frame: 52 weeks
|
To observe the frequency of adverse events following EPIAO® and EPREX® administration.
|
52 weeks
|
Occurence of anti-epoetin antibodies
Time Frame: 52 weeks
|
To monitor the occurrence of anti-epoetin antibodies among subjects following at least 52 weeks of therapy.
|
52 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: BOLONG MIAO, Ph.D, Shenyang Sunshine Pharmaceutical Co., LTD.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSS_EP_001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Anaemia
-
Penang Hospital, MalaysiaUnknownEnd Stage Renal Failure | Anaemia
-
GlaxoSmithKlineCompleted
-
JW PharmaceuticalCompletedChronic Renal Failure | AnaemiaKorea, Republic of
-
GlaxoSmithKlineQuintiles, Inc.; ERT: Clinical Trial Technology Solutions; Q2 Solutions; HemoCueCompleted
-
GlaxoSmithKlineCompletedAnaemiaUnited States, Australia, Korea, Republic of, Canada, Czechia, Norway, Spain, United Kingdom, Russian Federation, Germany, Sweden, Denmark, Poland, France, Hungary, Japan
-
GlaxoSmithKlinePPDCompletedAnaemiaUnited States, Germany, Canada, Sweden, Denmark, Norway
-
InCROM Europe Clinical ResearchCompletedAnaemia | Chronic Kidney Failure
-
GlaxoSmithKlineCompletedAnaemiaUnited States, Korea, Republic of, Argentina, Spain, Australia, Canada, Russian Federation, United Kingdom, Malaysia, Italy, Poland, Germany, India, Mexico, South Africa
-
GlaxoSmithKlineCompletedAnaemiaKorea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada
Clinical Trials on EPIAO®
-
Xiamen Amoytop Biotech Co., Ltd.Completed
-
Shenyang Sunshine Pharmaceutical Co., LTD.Navitas Life Sciences GmbHCompletedRenal AnemiaThailand, Russian Federation
-
West China HospitalNot yet recruiting
-
Ain Shams UniversityUnknownThalassemia IntermediaEgypt
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico